Polydrug abuse: a review of opioid and benzodiazepine combination use
- PMID: 22857878
- PMCID: PMC3454351
- DOI: 10.1016/j.drugalcdep.2012.07.004
Polydrug abuse: a review of opioid and benzodiazepine combination use
Abstract
This paper reviews studies examining the pharmacological interactions and epidemiology of the combined use of opioids and benzodiazepines (BZDs). A search of English language publications from 1970 to 2012 was conducted using PubMed and PsycINFO(®). Our search found approximately 200 articles appropriate for inclusion in this paper. While numerous reports indicate that the co-abuse of opioids and BZDs is ubiquitous around the world, the reasons for the co-abuse of these medications are not entirely clear. Though the possibility remains that opioid abusers are using BZDs therapeutically to self-medicate anxiety, mania or insomnia, the data reviewed in this paper suggest that BZD use is primarily recreational. For example, co-users report seeking BZD prescriptions for the purpose of enhancing opioid intoxication or "high," and use doses that exceed the therapeutic range. Since there are few clinical studies investigating the pharmacological interaction and abuse liability of their combined use, this hypothesis has not been extensively evaluated in clinical settings. As such, our analysis encourages further systematic investigation of BZD abuse among opioid abusers. The co-abuse of BZDs and opioids is substantial and has negative consequences for general health, overdose lethality, and treatment outcome. Physicians should address this important and underappreciated problem with more cautious prescribing practices, and increased vigilance for abusive patterns of use.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Conflict of interest statement
Only the authors listed are responsible for the content and preparation of this manuscript. The authors declare that over the past three years SDC, JDJ, and SM have all received compensation (in the form of partial salary support) from investigator-initiated studies supported by Reckitt-Benckiser Pharmaceuticals, Schering-Plough Corporation, Johnson & Johnson Pharmaceutical Research & Development, Endo Pharmaceuticals, and MediciNova. In addition, SDC has served as a consultant to the following companies: Abbott, Alpharma, Analgesic Research, BioDelivery Sciences, Cephalon, Inflexxion, King, Neuromed, Purdue, and Shire.
References
-
- Agmo A, Galvan A, Hcrcdia A, Morales M. Naloxone blocks the anti-anxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacol. 1995;120:186–194. - PubMed
-
- Aitken CK, Higgs PG, Hellard ME. Buprenorphine injection in Melbourne, Australia—an update. Drug Alcohol Rev. 2008;27:197–199. - PubMed
-
- American Academy of Pain Medicine (APM), American Pain Society (APS) The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13:6–8. - PubMed
-
- Ator NA. Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectrums. 2005;10:31–39. - PubMed
-
- Ator NA, Griffiths RR. Self-administration of barbiturates and benzodiazepines: a review. Pharmacol Biochem Behav. 1987;27:391–398. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
